



May 2, 2017

## **Amicus Therapeutics to Announce First Quarter 2017 Financial Results on May 9, 2017**

CRANBURY, N.J., May 02, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 9, 2017 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2017.

The call will be hosted by John F. Crowley, Chairman and Chief Executive Officer. He will be joined on the call by additional members of the Amicus management team. Interested participants and investors may access the conference call by dialing 877-303-5859 (U.S./Canada) or 678-224-7784 (international).

A live audio webcast can also be accessed via the Investors section of the Amicus Therapeutics corporate website at <http://ir.amicusrx.com/>, and will be archived for 30 days. Web participants are encouraged to go to the website 15 minutes prior to the start of the call to register, download, and install any necessary software.

A telephonic replay of the call will be available for seven days beginning at 11:30 a.m. ET on May 9, 2017. Access numbers for this replay are 855-859-2056 (U.S./Canada) and 404-537-3406 (international); conference ID: 16795077.

### **About Amicus Therapeutics**

[Amicus Therapeutics](http://ir.amicusrx.com/) (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus' lead programs in development include the small molecule pharmacological chaperone [migalastat](#) as a monotherapy for Fabry disease, [SD-101](#) for Epidermolysis Bullosa (EB), as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.

FOLD-G

CONTACTS:

Investors/Media:

Amicus Therapeutics

Sara Pellegrino

Senior Director, Investor Relations

[spellegrino@amicusrx.com](mailto:spellegrino@amicusrx.com)

(609) 662-5044

Media:

MWW PR

Sid Dinsay

[sdinsay@mww.com](mailto:sdinsay@mww.com)

(646) 381-9017

 Primary Logo

Source: Amicus Therapeutics, Inc

News Provided by Acquire Media